A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 5, 2011, Pages 1326-1332

  Guo, Zhenchao ^a   L'Italien, Gilbert J ^a,c   Jing, Yonghua ^a   Baker, Ross A ^a   Forbes, Robert A ^b   Hebden, Tony ^a   Kim, Edward ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Claims data; Drug safety; HbA1c; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; HEMOGLOBIN A1C; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; TIME FACTORS; UNITED STATES;

EID: 79957850183     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.020     Document Type: Article

References (33)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
2. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, 48:157-165.
3. Bushe C.J., Leonard B.E. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007, 68:1682-1690.
4. Castilla-Puentes R. Effects of psychotropics on glycosylated hemoglobin (HbA1c) in a cohort of bipolar patients. Bipolar Disord 2007, 9:772-778.
5. Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
6. Chen C-H, Lin T-Y, Chen T-T, Chen V C-H, Lin N-C, Shao W-C, Lu M-L. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. Prog Neuropsychopharmacol Biol Psychiatry 2011. http://doi:10.1016/j.pnpbp.2011.01.015.
7. Citrome L.L., Holt R.I., Zachry W.M., Clewell J.D., Orth P.A., Karagianis J.L., et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007, 41:1593-1603.
8. Clinical review Changes in weight, lipids, and glucose with quetiapine March 2009, (Accessed February 17, 2011). http://psychrights.org/research/Digest/NLPs/Seroquel/090409FDACommitteeBriefingDocs/Addendum-FDA-briefing-mat.pdf.
9. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
10. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
11. Hartung D.M., Wisdom J.P., Pollack D.A., Hamer A.M., Haxby D.G., Middleton L., et al. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 2008, 69:1540-1547.
12. Henderson D.C., Cagliero E., Copeland P.M., Louie P.M., Borba C.P., Fan X., et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007, 68:533-541.
13. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007, 22:433-443.
14. Lambert B.L., Cunningham F.E., Miller D.R., Dalack G.W., Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006, 164:672-681.
15. Leslie D.L., Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004, 161:1709-1711.
16. Li H., Isomaa B., Taskinen M.R., Groop L., Tuomi T. Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 2000, 23:589-594.
17. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160:290-296.
18. Luna B., Feinglos M.N. Drug-induced hyperglycemia. JAMA 2001, 286:1945-1948.
19. Manson J.E., Ajani U.A., Liu S., Nathan D.M., Hennekens C.H. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000, 109:538-542.
20. Newcomer J.W., Meyer J.M., Baker R.A., Eudicone J.M., Pikalov A., Vester-Blokland E., et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res 2008, 106:300-307.
21. Perez-Iglesias R., Crespo-Facorro B., Amado J.A., Garcia-Unzueta M.T., Ramirez-Bonilla M.L., Gonzalez-Blanch C., et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007, 68:1733-1740.
22. Ramaswamy K., Kozma C.M., Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 2007, 30:589-599.
23. Reaven G.M., Lieberman J.A., Sethuraman G., Kraemer H., Davis J.M., Blasey C., et al. Search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009, 43:997-1002.
24. Riedel A.A., Heien H., Wogen J., Plauschinat C.A. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007, 27:1102-1110.
25. Modern epidemiology 1998, Lippincott-Raven, Philadelphia, PA. 2nd ed. K.J. Rothman, S. Greenland (Eds.).
26. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
27. Saudek C.D., Derr R.L., Kalyani R.R. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006, 295:1688-1697.
28. Saudek C.D., Herman W.H., Sacks D.B., Bergenstal R.M., Edelman D., Davidson M.B. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008, 93:2447-2453.
29. Selvin E., Zhu H., Frederick L., Brancati F.L. Elevated A1C in adults without a history of diabetes in the U.S. Diabetes Care 2009, 32:828-833.
30. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561-566.
31. Shai I., Jiang R., Manson J.E., Stampfer M.J., Willett W.C., Colditz G.A., et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care 2006, 29:1585-1590.
32. Yood M.U., DeLorenze G., Quesenberry C.P., Oliveria S.A., Tsai A.L., Willey V.J., et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009, 18:791-799.
33. Zheng L., Mack W.J., Dagerman K.S., Hsiao J.K., Lebowitz B.D., Lyketsos C.G., et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009, 166:583-590.